Section 4 of 6
Clinical evidence
172 evidence topics · 30 sources
Study summaries
EPICS-III
Objective
Biochemical-response objective
Location and study date
Protocol-listed study region
Study design
Eligibility criteria
EPICS-III: inclusion-criteria excerpts
| Criterion | Quoted protocol text |
|---|---|
| UDCA-treated population | “Subjects on ursodeoxycholic acid (UDCA) for at least 12 months” |
| UDCA-intolerant population | “Subjects who are unable to tolerate UDCA” |
| ALP threshold | “ALP ≥ 1.67 x ULN” |
Treatment
Study outcomes
Rationale for using ALP and bilirubin biochemical response as the primary endpoint
EPICS-III: composite biochemical-response endpoint
| Component | Quoted definition |
|---|---|
| ALP threshold | “alkaline phosphatase (ALP) <1.67x upper limit of normal (ULN)” |
| ALP decrease relative to baseline | “≥15%” |
| Total bilirubin criterion | “total bilirubin ≤ ULN” |
| Gilbert’s syndrome alternative | “direct bilirubin ≤ULN in patients with known Gilbert's syndrome” |
| Assessment | “52 weeks” |
Statistical analysis description
Number of participants (Planned and analyzed)
Protocol-planned enrollment
| Population | Planned participants |
|---|---|
| Whole phase 2b/3 protocol | “192” |
Phase 3 enrollment reported in the topline release
| Population | Reported participants |
|---|---|
| Randomized phase 3 cohort | “149” |
EPICS-III: phase III results
| Endpoint or population | Saroglitazar | Placebo |
|---|---|---|
| Reported trial N | “148” |
Registry-reported enrollment across the combined study
| Population | Reported participants |
|---|---|
| Combined study enrollment | “196” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
EPICS-III: treatment differences
| Treatment difference | Quoted result |
|---|---|
| Biochemical response | “48% (95% CI: 35.3, 60.8) (p < 0.001)” |
| Least-squares mean ALP change | “-124.1 U/L (-40.1%)” |
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary
The primary endpoint is a biochemical surrogate, not a direct measure of transplantation or survival. The topline release reports 149 randomized participants, whereas the later NDA-supporting report gives a phase 3 trial population of 148; these totals are not reconciled in the retrieved evidence. The combined-study registry enrollment of 196 is a different population. Pruritus improvement was not statistically significant at 12 months.
EPICS-IV
Objective
ALP-normalization objective
Location and study date
Study design
Randomized, double-blind, placebo-controlled phase 3 design
Eligibility criteria
ALP-based eligibility
| Criterion | Quoted criterion |
|---|---|
| Screening ALP | “ALP > ULN to < 1.67xULN” |
Treatment
Saroglitazar magnesium: oral morning dosing
Study outcomes
Rationale for using ALP normalization as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Estimated participants |
|---|---|
| Randomized study | “89” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This study targets ALP above ULN but below 1.67 times ULN, rather than the higher ALP population in EPICS-III. Planned enrollment is 89 participants. The report contains a study design and eligibility record, but no treatment-effect estimates or observed safety results.
EPICS-V
Objective
Long-term clinical-outcomes objective
Location and study date
No evidence found.
Study design
Randomized phase 3b/4 study
Eligibility criteria
Treatment
Saroglitazar magnesium: oral morning dosing
Study outcomes
Rationale for using time to first clinical outcome event as the primary endpoint
Clinical-outcome observation period
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Estimated participants |
|---|---|
| Long-term randomized study | “386” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The planned study evaluates clinical outcomes over 48 months in a population with cirrhosis. Estimated enrollment is 386 participants. The retrieved evidence does not yet establish an effect on clinical events, and its cirrhotic eligibility population differs from the biochemical-response populations of earlier trials.
EPICS
Objective
Phase II proof-of-concept study: NCT03112681
Location and study date
No evidence found.
Study design
Double-blind randomized proof-of-concept design
Eligibility criteria
Treatment
Randomized daily treatment groups
| Treatment parameter | Saroglitazar 4 mg | Saroglitazar 2 mg | Placebo |
|---|---|---|---|
| Daily dose | “4 mg”View highlighted excerpt for this quote | “2 mg”View highlighted excerpt for this quote | “placebo”View highlighted excerpt for this quote |
| Treatment duration | “16 weeks”View highlighted excerpt for this quote | “16 weeks”View highlighted excerpt for this quote | “16 weeks”View highlighted excerpt for this quote |
Study outcomes
Rationale for using ALP reduction as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Phase II proof-of-concept study: study population
Randomized allocation
| Group | Participants |
|---|---|
| Saroglitazar 4 mg | “13”View highlighted excerpt for this quote |
| Saroglitazar 2 mg | “14”View highlighted excerpt for this quote |
| Placebo | “10”View highlighted excerpt for this quote |
Description of analysis sets
Primary analysis population
Results
Participant disposition
Study-drug discontinuations because of aminotransferase increases
| Group | Participants |
|---|---|
| All saroglitazar groups | “4”View highlighted excerpt for this quote |
| Saroglitazar 4 mg | “3”View highlighted excerpt for this quote |
| Saroglitazar 2 mg | “1”View highlighted excerpt for this quote |
Baseline characteristics
Baseline comparisons between treatment groups
Efficacy results
Phase II proof-of-concept study: week 16 ALP endpoints
| Week 16 endpoint | Saroglitazar 4 mg | Saroglitazar 2 mg | Placebo |
|---|---|---|---|
| Mean percentage ALP reduction | “49%”View highlighted excerpt for this quote | “51%”View highlighted excerpt for this quote | “3%”View highlighted excerpt for this quote |
| Least-squares mean ALP change, U/L | “-163.3”View highlighted excerpt for this quote | “-155.8”View highlighted excerpt for this quote | “-21.1”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
Week 16 PBC-40 itch domain
“The mean change from baseline on the itch domain of the PBC-40 questionnaire at Week 16 was -1.52, -1.08 and -2.31, respectively, for saroglitazar 4 mg, saroglitazar 2 mg and placebo groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, no worsening of pruritus was observed on the itch domain of the PBC-40 questionnaire” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“13 (35.1%) patients reported pruritus at baseline” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Participants with at least one treatment-emergent adverse event
| Outcome | Saroglitazar 4 mg | Saroglitazar 2 mg | Placebo |
|---|---|---|---|
| Participants, n (%) | “11 (84.6%)”View highlighted excerpt for this quote | “12 (85.7%)”View highlighted excerpt for this quote | “8 (80%)”View highlighted excerpt for this quote |
Aminotransferase increases after treatment discontinuation
Study limitations
Summary
This 37-participant trial lasted 16 weeks and tested 2 mg and 4 mg, not the later 1 mg magnesium regimen. Four participants discontinued treatment because of aminotransferase increases. The conference report describes one participant requiring immune suppression for suspected overlap syndrome, whereas the journal abstract summarizes recovery after discontinuation. Neither report establishes a long-term clinical-outcome benefit.
Investigator-stated limitation on the pruritus finding
“There were anecdotal reports of improvement in itching while on treatment with saroglitazar, but the current study does not provide any conclusive evidence, primarily because of the low prevalence of itching in study participants and the lack of additional measurements of itch severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Open-label single-arm study
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Open-label, single-arm study: regimen
| Field | Quoted finding |
|---|---|
| Regimen | “4 mg for 16 weeks”View highlighted excerpt for this quote |
Study outcomes
Rationale for using ALP reduction as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Open-label, single-arm study: enrollment
| Field | Quoted finding |
|---|---|
| Enrolled patients | “7”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Open-label, single-arm study: termination
| Field | Quoted finding |
|---|---|
| Reason for study termination | “lack of enrollment”View highlighted excerpt for this quote |
Baseline characteristics
Open-label, single-arm study: baseline characteristics
| Field | Quoted finding |
|---|---|
| Sex | “all patients were female”View highlighted excerpt for this quote |
| Mean age, years | “51.1 ± 10.0”View highlighted excerpt for this quote |
| Mean baseline ALP, U/L | “230 ± 103”View highlighted excerpt for this quote |
Efficacy results
Open-label, single-arm study: ALP response
| Field | Quoted finding |
|---|---|
| Mean ALP reduction at Week 16 | “48 ± 23%”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
Only seven participants were enrolled, all female, and the study ended because of lack of enrollment. Its open-label, single-arm design cannot separate treatment effects from changes that would have occurred without saroglitazar. The 16-week biochemical assessment does not establish a transplantation or survival benefit.
SARO.23.002
Objective
Extension objective
Location and study date
No evidence found.
Study design
Open-label extension design
Eligibility criteria
Eligibility after the parent trial
Treatment
Study outcomes
Rationale for using safety during extended treatment as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Registry-reported enrollment
| Population | Participants |
|---|---|
| Open-label extension | “102” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
Eligibility requires completion of the parent double-blind trial. This selects participants able to complete earlier treatment and does not recreate a randomized untreated comparator. The registry reports 102 participants, but the report contains no extension results.
RESPONSE
Objective
Biochemical-response objective
Location and study date
U.S. participation
| Population characteristic | Reported value |
|---|---|
| Participants enrolled in the United States | “Thirty-two percent” |
Study design
Randomized, double-blind trial duration
Eligibility criteria
Treatment
Study outcomes
Rationale for using ALP and bilirubin biochemical response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Early treatment discontinuation or missing month 12 data
Biochemical-response hypothesis test
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Month 12 biochemical response and alkaline phosphatase normalization: between-group differences
“A greater percentage of the patients in the seladelpar group than in the placebo group had a biochemical response (61.7% vs. 20.0%; difference, 41.7 percentage points; 95% confidence interval [CI], 27.7 to 53.4, P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Normalization of the alkaline phosphatase level also occurred in a greater percentage of patients who received seladelpar than of those who received placebo (25.0% vs. 0%; difference, 25.0 percentage points; 95% CI, 18.3 to 33.2, P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 193 patients who underwent randomization and treatment, 93.8% received ursodeoxycholic acid as standard-of-care background therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Month 6 pruritus: baseline average score at least 4
| Outcome | Seladelpar | Placebo |
|---|---|---|
| Analysis participants | “49” | “23” |
| Mean change in score, standard error | “-3.2 (0.3)” | “-1.7 (0.4)” |
Month 6 pruritus: least-squares mean difference against placebo
“Seladelpar resulted in a greater reduction in the score on the pruritus numerical rating scale than placebo (least-squares mean change from baseline, −3.2 vs. −1.7; least-squares mean difference, −1.5; 95% CI, −2.5 to −0.5, P = 0.005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Overall and serious adverse events
“Adverse events were reported in 86.7% of the patients in the seladelpar group and in 84.6% in the placebo group, and serious adverse events in 7.0% and 6.2%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence and severity of adverse events were similar in the two groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
This is comparator evidence, not a randomized comparison against saroglitazar. The primary endpoint was biochemical response after 12 months, and the pruritus analysis concerned a subgroup with baseline scores of at least 4. The prescribing information does not establish improved survival or prevention of liver decompensation.
ELATIVE
Objective
Biochemical-response objective
Location and study date
No evidence found.
Study design
Randomized multicenter design
Eligibility criteria
Treatment
Study outcomes
Rationale for using ALP and bilirubin biochemical response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Early treatment cessation or rescue treatment before week 52
Primary response analysis
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Week 52 biochemical response and alkaline phosphatase normalization: between-group differences
“A biochemical response (the primary end point) was observed in 51% of the patients (55 of 108) who received elafibranor and in 4% (2 of 53) who received placebo, for a difference of 47 percentage points (95% confidence interval [CI], 32 to 57; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The alkaline phosphatase level normalized in 15% of the patients in the elafibranor group and in none of the patients in the placebo group at week 52 (difference, 15 percentage points; 95% CI, 6 to 23; P=0.002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with elafibranor resulted in significantly greater improvements in relevant biochemical indicators of cholestasis than placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Week 52 pruritus: moderate-to-severe pruritus subgroup
“Among patients who had moderate-to-severe pruritus (44 patients in the elafibranor group and 22 in the placebo group), the least-squares mean change from baseline through week 52 on the WI-NRS did not differ significantly between the groups (−1.93 vs. −1.15; difference, −0.78; 95% CI, −1.99 to 0.42; P=0.20).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Study limitations
Summary
This comparator trial does not provide a head-to-head estimate against saroglitazar. Its primary endpoint was biochemical response at 52 weeks. The population was 96% female, and eligibility excluded decompensated cirrhosis, limiting extrapolation to that population.
BEZURSO
Objective
Location and study date
No evidence found.
Study design
Double-blind, placebo-controlled phase 3 design: duration
Eligibility criteria
Inadequate UDCA response criterion
Treatment
Bezafibrate daily dose in addition to UDCA
Study outcomes
Rationale for using complete biochemical response as the primary endpoint
Complete biochemical-response definition
Additional primary-response criterion
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary
This 100-participant comparator trial lasted 24 months and evaluated bezafibrate added to UDCA, not saroglitazar. Its complete biochemical-response definition differs from the EPICS-III composite, so the response percentages are not interchangeable across studies.
ZYH1 first-in-human study
Objective
Pharmacokinetics, safety, and tolerability objective
Location and study date
Study design
Eligibility criteria
Healthy-volunteer age range
| Criterion | Age, years |
|---|---|
| Minimum | “18”View highlighted excerpt for this quote |
| Maximum | “45”View highlighted excerpt for this quote |
Treatment
Single-dose range and food/sex substudy
| Study component | Dose |
|---|---|
| Lowest ascending dose, mg | “0.125”View highlighted excerpt for this quote |
| Highest ascending dose, mg | “128”View highlighted excerpt for this quote |
| Food/sex substudy dose, mg | “1”View highlighted excerpt for this quote |
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment accounting
| Population | Participants |
|---|---|
| Unique participants overall | “96”View highlighted excerpt for this quote |
| Part I: healthy men | “88”View highlighted excerpt for this quote |
| Part II: men and women | “16”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Part I completion
| Population | Participants |
|---|---|
| Completed Part I | “87”View highlighted excerpt for this quote |
Baseline characteristics
Part II sex distribution
| Sex | Participants |
|---|---|
| Male | “8”View highlighted excerpt for this quote |
| Female | “8”View highlighted excerpt for this quote |
Efficacy results
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Study limitations
Summary
This single-dose study enrolled healthy volunteers, not participants with PBC. Its 96 unique participants included eight men who participated in both parts, so the part-specific enrollments should not be added without accounting for overlap. It does not establish efficacy or repeated-dose safety in PBC.
Saroglitazar magnesium food-effect study
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment and analyzed population
| Population | Participants |
|---|---|
| Enrolled | “54”View highlighted excerpt for this quote |
| Completed and analyzed | “50”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Study completion
| Disposition | Participants |
|---|---|
| Completed | “50”View highlighted excerpt for this quote |
Baseline characteristics
No evidence found.
Efficacy results
Food effect: healthy volunteers, 4-mg tablet
“food reduced Cmax (maximum concentration) of saroglitazar by 30%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“there is no impact of food on the extent of absorption of saroglitazar.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Reported adverse-event severity
Study limitations
Summary
The study evaluated a single 4 mg tablet in healthy volunteers under fed and fasting conditions. Fifty of 54 enrolled participants completed and were analyzed. These results do not directly establish food effects after repeated 1 mg dosing in PBC.
SARO.19.003 part A
Objective
Hepatic-impairment pharmacokinetic objective
Location and study date
No evidence found.
Study design
Single-dose parallel-group study
Eligibility criteria
Hepatic-function comparison
Treatment
Single-dose hepatic-impairment cohorts
| Regimen | Dose |
|---|---|
| Oral saroglitazar | “4-mg” |
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Published hepatic-impairment cohorts
| Population | Participants |
|---|---|
| Hepatic impairment | “Thirty-two” |
| Normal hepatic function | “23” |
Description of analysis sets
Pharmacokinetic analysis
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Hepatic impairment: single-dose study
| Population or parameter | Quoted finding |
|---|---|
| Mild and moderate hepatic impairment | “did not significantly affect the PK of saroglitazar” |
| Severe hepatic impairment: exposure | “increased 3-fold” |
| Severe hepatic impairment: clearance | “61% lower” |
| Severe hepatic impairment: authors’ qualification | “may require close monitoring or dose adjustments” |
Non-cirrhotic cholestatic liver disease: comparison with controls
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Single-dose tolerability
Study limitations
Summary
Single-dose pharmacokinetics do not establish repeated-dose safety or clinical efficacy. The 32 participants with hepatic impairment and 23 controls describe the published hepatic-impairment cohorts, not every cohort subsequently reported under this protocol. Severe impairment increased exposure, limiting extrapolation from mild or moderate impairment.
SARO.19.003 part B
Objective
Pharmacokinetic and pharmacodynamic assessment
Location and study date
Study design
Open-label multiple-dose study
Eligibility criteria
PBC-cirrhosis population
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment including replacement
| Population | Participants |
|---|---|
| Enrolled | “19” |
Description of analysis sets
Pharmacokinetic analysis
Results
Participant disposition
Replacement after withdrawal
Baseline characteristics
Efficacy results
Moderate hepatic impairment: exposure and clearance
ALP reduction after four weeks in participants with abnormal baseline ALP
| Outcome | Reported reduction |
|---|---|
| ALP reduction | “17–40%” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Serious event in a participant receiving 2 mg
Study limitations
Summary
The study was open-label and lasted four weeks. It characterizes short-term pharmacokinetics rather than comparative clinical efficacy. Increased exposure in moderate hepatic impairment and the small cohort restrict extrapolation to longer treatment or broader cirrhotic populations.
SARO.19.004
Objective
Renal-impairment pharmacokinetic objective
Location and study date
No evidence found.
Study design
Single-dose design
Eligibility criteria
Severe renal-impairment population
Treatment
Single oral dose
| Treatment | Dose |
|---|---|
| Saroglitazar, mg | “2” |
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Pharmacokinetic analysis
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Single-dose exposure relative to controls
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Single-dose safety assessment
Study limitations
Summary
This single-dose comparison included eight participants with severe renal impairment and eight controls. It does not establish repeated-dose safety, PBC efficacy, or dosing in participants with combined hepatic and renal impairment.
SARO.24.003
Objective
Pharmacokinetic objective
Location and study date
No evidence found.
Study design
Open-label phase 1 design
Eligibility criteria
Moderate hepatic impairment eligibility
| Criterion | Quoted value |
|---|---|
| Child-Pugh Turcotte score | “7 to 9” |
Treatment
Alternate-day regimen
| Regimen characteristic | Quoted value |
|---|---|
| Saroglitazar magnesium tablet strength | “1 mg” |
| Dosing schedule | “alternate days” |
| Duration | “29 days” |
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Estimated participants |
|---|---|
| Single-arm pharmacokinetic study | “6” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
The planned study contains six participants and no randomized control group. It evaluates alternate-day administration in moderate hepatic impairment. The record provides no observed pharmacokinetic or safety results.